Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.58 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457205 | 0.86 | CRBN (0.61) | CRBNDDB1GSPT1HDAC1ALDH1A1 | |
| SCHEMBL30313158 | 0.86 | CRBN (0.65) | CRBNDDB1GSPT1HDAC1IKZF3 | |
| SCHEMBL23240143 | 0.86 | CRBN (0.56) | CRBNDDB1GSPT1HDAC1IKZF3 | |
| SCHEMBL1413539 | 0.86 | CRBN (0.57) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL4451281 | 0.86 | CRBN (0.60) | CRBNDDB1GSPT1HDAC1ALDH1A1 | |
| SCHEMBL4450638 | 0.85 | CRBN (0.60) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL1413835 | 0.84 | CRBN (0.68) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL1962541 | 0.83 | DDB1 (0.71) | CRBNDDB1HDAC1IKZF3 | |
| SCHEMBL1413642 | 0.83 | CRBN (0.64) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL25210651 | 0.82 | CRBN (0.68) | CRBNDDB1GSPT1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| WO-2014172429-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| WO-2008027542-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885DDB1 820/4885GSPT1 861/4885 |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885DDB1 233/4885GSPT1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.